Healthcare & Wellness
·
3 min read
Tempus AI Acquires Personalis for $1.5 Billion to Expand Into Cancer Recurrence Monitoring
Tempus AI's $1.5 billion acquisition of Personalis combines AI-powered cancer diagnosis with molecular residual disease testing to create an integrated surveillance platform for post-treatment recurrence monitoring.
6d ago